May 6, 2021 08:01 AM EDT
FDA+
Manufacturing

Re­call re­port: Acel­la pulls thy­roid tablets af­ter a raft of side ef­fect re­ports; mis­la­bel­ing caus­es Pfiz­er's Hos­pi­ra to yank 2 lots of anes­thet­ics

Josh Sullivan

Acel­la Phar­ma­ceu­ti­cals has pulled its NP Thy­roid tablets off US shelves af­ter rou­tine test­ing found dif­fer­ent ver­sions of the drug not hit­ting po­ten­cy marks. In …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times